Some prominent biotech execs are stepping up to support the launch of a company called Octave Bioscience, which has been building a platform to guide the treatment of patients with multiple sclerosis.
Ex-Biogen CEO and current Vir chief George Scangos is taking a board position, alongside Section 32 managing partner Michael Pellini, who is backing the company’s $14 million A round.
Scangos helped change the standard of care in MS with the launch of Tecfidera at Biogen 5 years ago. But in MS, patients have to be constantly monitored to see if they’re getting the best care, switching drugs as needed. That’s where Octave proposes to step in, using the latest diagnostic tools to stay on top of each case.
“(P)hysicians can miss important shifts in disease status or co-morbidities between office visits,” says Octave founder William Hagstrom in a statement. “Octave’s care management solution was designed to start with a measurement system that includes assessing a patient’s biology via select biomarkers tied to inflammatory disease activity and neurodegeneration. This is further complemented by technology to continuously track patients’ symptoms and disease trajectory using sensors and mobile tools. Additionally, we are optimizing MRIs to improve contextualization, quantification and serial changes over time. Each of these capabilities provide high-resolution, 360-degree, longitudinal data streams to integrate into our care platform.”
Image: George Scangos.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,100+ biopharma pros who read Endpoints News by email every day.Free Subscription